HOXB13 regulates the prostate-derived ets factor: Implications for prostate cancer cell invasion

International Journal of Oncology

Volumn 45, Issue 2, 2014, Pages 869-876

  Kim, In Je ^a   Kang, Taek Won ^a   Jeong, Taeoh ^a   Kim, Young Rang ^a   Jung, Chaeyong ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Ets; HOXB13; MMP 9; PDEF; Prostate cancer; Survivin

Indexed keywords

GELATINASE B; PROSTATE DERIVED ETS FACTOR; PROTEIN HOXB13; SURVIVIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; HOMEODOMAIN PROTEIN; HOXB13 PROTEIN, HUMAN; SPDEF PROTEIN, HUMAN; TRANSCRIPTION FACTOR ETS;

ARTICLE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; ENZYME ACTIVITY; GENE TARGETING; HUMAN; HUMAN CELL; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; WESTERN BLOTTING; ZYMOGRAPHY; CELL MOTION; GENETIC TRANSFECTION; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR INVASION;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; HOMEODOMAIN PROTEINS; HUMANS; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84902602384     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2485     Document Type: Article

References (39)

1. Sreenath T, Orosz A, Fujita K and Bieberich CJ: Androgen-independent expression of hoxb-13 in the mouse prostate. Prostate 41: 203-207, 1999. (Pubitemid 29508615)
2. Ma XJ, Wang Z, Ryan PD, et al: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5: 607-616, 2004. (Pubitemid 38748922)
3. Miao J, Wang Z, Provencher H, et al: HOXB13 promotes ovarian cancer progression. Proc Natl Acad Sci USA 104: 17093-17098, 2007. (Pubitemid 350210997)
4. Zhao Y, Yamashita T and Ishikawa M: Regulation of tumor invasion by HOXB13 gene overexpressed in human endometrial cancer. Oncol Rep 13: 721-726, 2005.
5. Edwards S, Campbell C, Flohr P, et al: Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer. Br J Cancer 92: 376-381, 2005. (Pubitemid 40343155)
6. Jung C, Kim RS, Lee SJ, Wang C and Jeng MH: HOXB13 homeodomain protein suppresses the growth of prostate cancer cells by the negative regulation of T-cell factor 4. Cancer Res 64: 3046-3051, 2004. (Pubitemid 38581403)
7. Jung C, Kim RS, Zhang HJ, Lee SJ and Jeng MH: HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res 64: 9185-9192, 2004. (Pubitemid 39665535)
8. Kim SD, Park RY, Kim YR, et al: HOXB13 is co-localized with androgen receptor to suppress androgen-stimulated prostate-specific antigen expression. Anat Cell Biol 43: 284-293, 2010.
9. Kim YR, Oh KJ, Park RY, et al: HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling. Mol Cancer 9: 124, 2010.
10. Kim YR, Kim IJ, Kang TW, et al: HOXB13 downregulates intracellular zinc and increases NF-kappaB signaling to promote prostate cancer metastasis. Oncogene: 7 Oct, 2013 (Epub ahead of print). doi:10.1038/onc.2013.404 2013.
11. Sharrocks AD, Brown AL, Ling Y and Yates PR: The ETS-domain transcription factor family. Int J Biochem Cell Biol 29: 1371-1387, 1997. (Pubitemid 28153488)
12. Clark JP and Cooper CS: ETS gene fusions in prostate cancer. Nat Rev Urol 6: 429-439, 2009.
13. Kumar-Sinha C, Tomlins SA and Chinnaiyan AM: Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8: 497-511, 2008.
14. Tomlins SA, Bjartell A, Chinnaiyan AM, et al: ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 56: 275-286, 2009.
15. Oettgen P, Finger E, Sun Z, et al: PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem 275: 1216-1225, 2000. (Pubitemid 30051174)
16. Johnson TR, Koul S, Kumar B, et al: Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: regulation of MMP 9 by PDEF. Mol Cancer 9: 148, 2010.
17. Gu X, Zerbini LF, Otu HH, et al: Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res 67: 4219-4226, 2007. (Pubitemid 46815068)
18. Turner DP, Findlay VJ, Moussa O, et al: Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression. Prostate 71: 1723-1735, 2011.
19. Ghadersohi A, Pan D, Fayazi Z, Hicks DG, Winston JS and Li F: Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res Treat 102: 19-30, 2007.
20. Lynch CC and Matrisian LM: Matrix metalloproteinases in tumor-host cell communication. Differentiation 70: 561-573, 2002. (Pubitemid 36194320)
21. Zhang M, Latham DE, Delaney MA and Chakravarti A: Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24: 2474-2482, 2005. (Pubitemid 40593038)
22. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM and Watson DK: PDEF expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 63: 4626-4631, 2003. (Pubitemid 36951040)
23. Feldman RJ, Sementchenko VI and Watson DK: The epithelial-specific Ets factors occupy a unique position in defining epithelial proliferation, differentiation and carcinogenesis. Anticancer Res 23: 2125-2131, 2003. (Pubitemid 36897172)
24. Moussa O, Turner DP, Feldman RJ, et al: PDEF is a negative regulator of colon cancer cell growth and migration. J Cell Biochem 108: 1389-1398, 2009.
25. Turner DP, Findlay VJ, Kirven AD, Moussa O and Watson DK: Global gene expression analysis identifies PDEF transcriptional networks regulating cell migration during cancer progression. Mol Biol Cell 19: 3745-3757, 2008.
26. Turner DP, Moussa O, Sauane M, Fisher PB and Watson DK: Prostate-derived ETS factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer. Cancer Res 67: 1618-1625, 2007. (Pubitemid 46383387)
27. Schaefer JS, Sabherwal Y, Shi HY, et al: Transcriptional regulation of p21/CIP1 cell cycle inhibitor by PDEF controls cell proliferation and mammary tumor progression. J Biol Chem 285: 11258-11269, 2010.
28. Findlay VJ, Turner DP, Yordy JS, et al: Prostate-derived ETS factor regulates epithelial-to-mesenchymal transition through both SLUG-dependent and independent mechanisms. Genes Cancer 2: 120-129, 2011.
29. Ma XJ, Hilsenbeck SG, Wang W, et al: The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24: 4611-4619, 2006. (Pubitemid 46630959)
30. Ghadersohi A, Odunsi K, Zhang S, et al: Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. Int J Cancer 123: 1376-1384, 2008.
31. Ghadersohi A, Sharma S, Zhang S, et al: Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer. Prostate 71: 1178-1188, 2011.
32. Fromont G, Chene L, Latil A, et al: Molecular profiling of benign prostatic hyperplasia using a large scale real-time reverse transcriptase- polymerase chain reaction approach. J Urol 172: 1382-1385, 2004. (Pubitemid 39249725)
33. Jeong TO, Oh KJ, Xuan Nguyen NT, et al: Evaluation of HOXB13 as a molecular marker of recurrent prostate cancer. Mol Med Rep 5: 901-904, 2012.
34. Johnson PH, Walker RP, Jones SW, et al: Multiplex gene expression analysis for high-throughput drug discovery: screening and analysis of compounds affecting genes overexpressed in cancer cells. Mol Cancer Ther 1: 1293-1304, 2002.
35. Birkenkamp-Demtroder K, Olesen SH, Sorensen FB, et al: Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 54: 374-384, 2005. (Pubitemid 40299094)
36. Hoek K, Rimm DL, Williams KR, et al: Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 64: 5270-5282, 2004. (Pubitemid 39006547)
37. Jung C, Kim RS, Zhang H, et al: HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation. Br J Cancer 92: 2233-2239, 2005. (Pubitemid 40966262)
38. Komuves LG, Ma XK, Stelnicki E, Rozenfeld S, Oda Y and Largman C: HOXB13 homeodomain protein is cytoplasmic throughout fetal skin development. Dev Dyn 227: 192-202, 2003. (Pubitemid 36666748)
39. Okuda H, Toyota M, Ishida W, et al: Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma. Oncogene 25: 1733-1742, 2006.